Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 440, 278 (16 March 2006) | doi:10.1038/440278b; Published online 15 March 2006
Open Innovation Challenges
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
nature jobs
Group Leader Positions
- The International Iberian Nanotechnology Laboratory (INL)
- Braga Portugal
Group Leader Positions
- IMP
- Vienna Austria
Lyme vaccine demonized by advocacy groups
Edward McSweegan1
- 1692 Barrister Court, Crofton, Maryland 21114, USA
As a microbiologist who managed a federal programme on Lyme disease in the 1990s, I consider that any new clinical trials of a vaccine candidate based on the protein OspA, as mentioned in your News Feature "Uphill struggle" (Nature 439, 524–525; 2006), should be confined to Europe, for three reasons.First, Lyme disease is non-communicable, readily treatable with common antibiotics and geographically localized in the United States.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantationBone Marrow Transplantation Original Article

